Medications for anxiety disorders
Pro Research Analysisby 
Searched over 200M research papers
First-Line Medications for Anxiety Disorders: SSRIs and SNRIs
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are widely recognized as the first-line medications for treating anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder 1234+4 MORE. These medications are preferred due to their effectiveness and relatively favorable side effect profiles. Examples include sertraline (an SSRI) and venlafaxine extended release (an SNRI) . SSRIs and SNRIs are recommended for long-term use, typically for at least 6 to 12 months after remission 164.
Second-Line and Adjunctive Medications for Anxiety Disorders
Other medications may be considered when first-line treatments are not effective or tolerated. These include:
- Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), which are generally reserved for second- or third-line use due to tolerability issues 34.
- Buspirone, an azapirone, is used especially for GAD 236.
- Pregabalin and gabapentin, which are calcium channel modulators, can be effective, particularly for GAD 126.
- Mirtazapine and other mixed antidepressants may be considered in some cases .
- Antipsychotics and anticonvulsants may be used as adjuncts in treatment-resistant cases 23.
- Hydroxyzine (an antihistamine), propranolol and clonidine (adrenergic agents) are sometimes used for specific symptoms or situations .
Benzodiazepines: Limited Role Due to Risks
Benzodiazepines can be effective for acute anxiety and short-term relief, but they are not recommended for routine or long-term use due to risks of dependence, cognitive impairment, and withdrawal syndromes 1234+2 MORE. Their use is generally limited to specific situations or when other treatments have failed.
Novel and Emerging Medications for Anxiety Disorders
Recent research has focused on developing new medications with different mechanisms of action, as current options are not always effective or well-tolerated for all patients 278. Novel agents under investigation include:
- Glutamate modulators (e.g., ketamine, riluzole, xenon) 278.
- Neurosteroids (e.g., aloradine, PH94B) 278.
- Cannabinoids (e.g., cannabidiol) 27.
- Neuropeptides and other agents targeting new neurotransmitter systems 27.
- D-cycloserine, MDMA, L-DOPA, and cannabinoids are being studied as augmentative strategies to enhance the effectiveness of psychotherapy, especially exposure-based treatments .
Despite these efforts, only a few new medications have been approved for anxiety disorders in recent years, such as delayed-release duloxetine and extended-release lorazepam . However, several promising agents are currently in phase III clinical trials .
Considerations in Medication Selection
When choosing a medication for anxiety disorders, clinicians should consider factors such as efficacy, side effects, drug interactions, patient preferences, comorbid conditions, and cost 610. Treatment is often most effective when combined with psychotherapy, particularly cognitive behavioral therapy (CBT), which has strong evidence for efficacy 16910.
Conclusion
SSRIs and SNRIs remain the first-line pharmacological treatments for most anxiety disorders, with other options available for specific cases or when first-line agents are not suitable. Benzodiazepines are generally avoided for long-term use due to safety concerns. Research into novel medications is ongoing, with several new agents showing promise in clinical trials. Medication choice should be individualized, and combining pharmacotherapy with psychotherapy often yields the best outcomes for patients with anxiety disorders.
Sources and full results
Most relevant research papers on this topic